Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at The Liver
Meeting® 2018
– GS-9674 Granted Orphan Drug Designation by the U.S. Food and Drug Administration –
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that treatment with GS-9674, an investigational, selective, nonsteroidal
farnesoid X receptor (FXR) agonist, led to significant improvements in liver biochemistry and markers of cholestasis in patients
with primary sclerosing cholangitis (PSC). Data were presented at The Liver Meeting® 2018 in San Francisco.
PSC is a rare, chronic condition that causes the network of ducts that drain bile from the liver to become inflamed and scarred
over time. Progressive damage to the bile ducts in patients with PSC can lead to cirrhosis, liver failure, and cholangiocarcinoma
(cancer of the bile ducts). Fatigue, pruritus and abdominal discomfort are common symptoms of PSC that can greatly impact patients’
quality of life. There are no approved treatments for PSC.
“Gilead is committed to applying our research expertise in liver disease to address this debilitating condition which may lead
to serious liver-related complications for PSC patients,” said John McHutchison, AO, MD, Chief Scientific Officer, Head of Research
and Development, Gilead Sciences. “These latest results from our Phase 2 program of GS-9674 are a positive step forward in the
search for effective therapy.”
In the Phase 2, double-blind, placebo-controlled trial, 52 non-cirrhotic patients with PSC were randomized to receive GS-9674
100 mg (n=22), GS-9674 30 mg (n=20), or placebo (n=10) orally once daily for 12 weeks. After 12 weeks of treatment, patients
receiving GS-9674 100 mg demonstrated significant improvements in liver biochemistry tests, with a median reduction in serum
alkaline phosphatase (ALP) of 20.5 percent vs. an increase of 3.4 percent with placebo (p=0.029), median reduction in
gamma-glutamyl transferase (GGT) of 30.3 percent vs. an increase of 1.1 percent with placebo (p<0.001), median reduction in
alanine aminotransferase (ALT) of 49.4 percent vs. 12.9 percent with placebo (p=0.009), and a median reduction in aspartate
aminotransferase (AST) of 42.3 percent vs. 10.8 percent with placebo (p=0.019). In both groups treated with GS-9674, reduced serum
levels of C4, an intermediate in the synthesis of bile acids, were observed compared with placebo (-23.2 percent in the 100 mg
group, p=0.21; and -30.5 percent in the 30 mg group, p=0.024). Reductions in serum bile acids were greatest with the 100 mg
dose.
GS-9674 was well tolerated and the incidence of Grade 2 or 3 pruritus was numerically lower with GS-9674 100 mg (13.6 percent)
and 30 mg (20 percent) compared with placebo (40 percent). There were no elevations in serum lipids. Treatment was discontinued due
to adverse events in three patients treated with GS-9674 100 mg (14 percent), including one discontinuation due to pruritus, and
one patient with placebo (10 percent).
A separate analysis of health-related patient-reported outcome measures (PROs) among patients enrolled in the Phase 2 trial
demonstrated significant impairment of PRO scores among PSC patients with pruritus or fatigue. In the evaluation, patients treated
with GS-9674 100 mg experienced significant improvement of the Primary Biliary Cholangitis – 40 (PBC-40) Emotional score (p=0.04)
compared with patients treated with placebo.
“Patients living with PSC urgently need effective and tolerable treatment options,” said Michael Trauner, MD, presenting author
and Head of the Division of Gastroenterology and Hepatology at the Medical University of Vienna, Austria. “These Phase 2 results
are encouraging in terms of beneficial changes in liver biochemistry, markers of bile acid homeostasis, and patient-reported
outcome measures. We look forward to further determining the safety and efficacy of this investigational agent.”
GS-9674 is an investigational compound and is not approved by the U.S. Food & Drug Administration (FDA) or any other
regulatory authority. Its safety and efficacy have not been determined.
About GS-9674
GS-9674 is an investigational, selective, non-steroidal agonist of the farnesoid X receptor (FXR), a nuclear hormone receptor
that is highly expressed in the gastrointestinal tract and liver. FXR is the primary regulator of bile acid synthesis and plays
important roles in glucose and lipid metabolism. GS-9674 is being investigated for the treatment of PSC, primary biliary
cholangitis (PBC), and advanced fibrosis due to nonalcoholic steatohepatitis (NASH), a chronic and progressive liver disease
characterized by fat accumulation and inflammation in the liver, which can lead to scarring or fibrosis. GS-9674 is an
investigational agent and its efficacy and safety have not been determined.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to transform and simplify care for people with
life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with
headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at
www.gilead.com.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995 that are subject to risks, uncertainties and other factors, including Gilead’s ability to complete the clinical trial programs
evaluating GS-9674 for the treatment of primary sclerosing cholangitis in the currently anticipated timelines, or at all. In
addition, there is the possibility of unfavorable results from additional clinical trials involving GS-9674. Further, it is
possible that Gilead may make a strategic decision to discontinue development of GS-9674, and as a result, GS-9674 may never be
successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from
those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These
and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, as
filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available
to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at
www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or
1-650-574-3000
![](http://cts.businesswire.com/ct/CT?id=bwnews&sty=20181109005274r1&sid=mstr3&distro=nx&lang=en)
Gilead Sciences, Inc.
Investors
Sung Lee, 650-524-7792
or
Media
Arran Attridge, 650-425-8975
View source version on businesswire.com: https://www.businesswire.com/news/home/20181109005274/en/